WO2022231261A1 - 잔틴 옥시다아제 저해제 합성을 위한 중간체의 제조 방법 - Google Patents
잔틴 옥시다아제 저해제 합성을 위한 중간체의 제조 방법 Download PDFInfo
- Publication number
- WO2022231261A1 WO2022231261A1 PCT/KR2022/005925 KR2022005925W WO2022231261A1 WO 2022231261 A1 WO2022231261 A1 WO 2022231261A1 KR 2022005925 W KR2022005925 W KR 2022005925W WO 2022231261 A1 WO2022231261 A1 WO 2022231261A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- formula
- hydrogen
- halogen
- compound
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 18
- 239000003064 xanthine oxidase inhibitor Substances 0.000 title abstract description 7
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 title abstract description 6
- 230000015572 biosynthetic process Effects 0.000 title abstract description 5
- 238000003786 synthesis reaction Methods 0.000 title abstract description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 28
- 239000001257 hydrogen Substances 0.000 claims description 28
- 125000000217 alkyl group Chemical group 0.000 claims description 23
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 18
- 229910052736 halogen Inorganic materials 0.000 claims description 16
- 150000002367 halogens Chemical group 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 13
- 239000010949 copper Substances 0.000 claims description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 8
- 229910052802 copper Inorganic materials 0.000 claims description 8
- 239000003446 ligand Substances 0.000 claims description 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 4
- 239000003054 catalyst Substances 0.000 claims description 4
- 238000005859 coupling reaction Methods 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 3
- 150000002923 oximes Chemical class 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 3
- 239000008096 xylene Substances 0.000 claims description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- ATGAWOHQWWULNK-UHFFFAOYSA-I pentapotassium;[oxido(phosphonatooxy)phosphoryl] phosphate Chemical compound [K+].[K+].[K+].[K+].[K+].[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O ATGAWOHQWWULNK-UHFFFAOYSA-I 0.000 claims description 2
- SSJXIUAHEKJCMH-OLQVQODUSA-N (1s,2r)-cyclohexane-1,2-diamine Chemical compound N[C@H]1CCCC[C@H]1N SSJXIUAHEKJCMH-OLQVQODUSA-N 0.000 claims 1
- JRHPOFJADXHYBR-UHFFFAOYSA-N 1-n,2-n-dimethylcyclohexane-1,2-diamine Chemical compound CNC1CCCCC1NC JRHPOFJADXHYBR-UHFFFAOYSA-N 0.000 claims 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 claims 1
- KVKFRMCSXWQSNT-UHFFFAOYSA-N n,n'-dimethylethane-1,2-diamine Chemical compound CNCCNC KVKFRMCSXWQSNT-UHFFFAOYSA-N 0.000 claims 1
- 229910000027 potassium carbonate Inorganic materials 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 3
- 201000005569 Gout Diseases 0.000 description 12
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 11
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 11
- 150000002431 hydrogen Chemical group 0.000 description 11
- 229940116269 uric acid Drugs 0.000 description 11
- 229960003459 allopurinol Drugs 0.000 description 6
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 108010093894 Xanthine oxidase Proteins 0.000 description 4
- 102100033220 Xanthine oxidase Human genes 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 3
- JLQQRYOWGCIMMZ-UHFFFAOYSA-N 1-(3-cyano-1-propan-2-ylindol-5-yl)pyrazole-4-carboxylic acid Chemical compound C=1C=C2N(C(C)C)C=C(C#N)C2=CC=1N1C=C(C(O)=O)C=N1 JLQQRYOWGCIMMZ-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- SSJXIUAHEKJCMH-UHFFFAOYSA-N cyclohexane-1,2-diamine Chemical compound NC1CCCCC1N SSJXIUAHEKJCMH-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- FTSLZSHWVUNXLF-UHFFFAOYSA-N ethyl 1-(1h-indol-5-yl)pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=CC=C(NC=C2)C2=C1 FTSLZSHWVUNXLF-UHFFFAOYSA-N 0.000 description 2
- KACZQOKEFKFNDB-UHFFFAOYSA-N ethyl 1h-pyrazole-4-carboxylate Chemical compound CCOC(=O)C=1C=NNC=1 KACZQOKEFKFNDB-UHFFFAOYSA-N 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000004144 purine metabolism Effects 0.000 description 2
- 238000013341 scale-up Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 229940075420 xanthine Drugs 0.000 description 2
- XSFVQEHUVOVFOW-UHFFFAOYSA-N 1,10-phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1.C1=CN=C2C3=NC=CC=C3C=CC2=C1 XSFVQEHUVOVFOW-UHFFFAOYSA-N 0.000 description 1
- MFUGHYOIMCMYQV-UHFFFAOYSA-N 1-N,2-N-dimethylcyclohexane-1,2-diamine Chemical compound CNC1CCCCC1NC.CNC1CCCCC1NC MFUGHYOIMCMYQV-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- USASUEYARBQNBM-UHFFFAOYSA-N 1h-indol-2-ylboronic acid Chemical compound C1=CC=C2NC(B(O)O)=CC2=C1 USASUEYARBQNBM-UHFFFAOYSA-N 0.000 description 1
- VHADYSUJZAPXOW-UHFFFAOYSA-N 1h-indol-5-ylboronic acid Chemical compound OB(O)C1=CC=C2NC=CC2=C1 VHADYSUJZAPXOW-UHFFFAOYSA-N 0.000 description 1
- VXWVFZFZYXOBTA-UHFFFAOYSA-N 5-bromo-1h-indole Chemical compound BrC1=CC=C2NC=CC2=C1 VXWVFZFZYXOBTA-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 1
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 108010092464 Urate Oxidase Proteins 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 229960005101 febuxostat Drugs 0.000 description 1
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- BCUSQLYIPWXJKK-UHFFFAOYSA-N n,n'-dimethylethane-1,2-diamine Chemical compound CNCCNC.CNCCNC BCUSQLYIPWXJKK-UHFFFAOYSA-N 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- HXNFUBHNUDHIGC-UHFFFAOYSA-N oxypurinol Chemical compound O=C1NC(=O)N=C2NNC=C21 HXNFUBHNUDHIGC-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000004147 pyrimidine metabolism Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Definitions
- the present invention relates to a method for preparing a main intermediate for the synthesis of a xanthine oxidase inhibitor, and more particularly, to a novel method for preparing an intermediate of the following formula (2) using a low-cost starting material and a C-N coupling reaction:
- R1 is hydrogen
- R2 is hydrogen, halogen, C 1 -C 7 alkyl, C 1 -C 7 alkoxy-C 1 -C 7 alkyl or phenyl;
- R3 is hydrogen; C 1 -C 7 alkyl unsubstituted or substituted by a substituent selected from halogen, C 3 -C 7 cycloalkyl and O-R 6 , wherein R 6 represents C 1 -C 4 alkyl; C 3 -C 7 cycloalkyl; or (wherein W represents O or S, R7 represents hydrogen or C 1 -C 4 alkyl, and n is an integer from 0 to 3);
- R4 is hydrogen, halogen or C 1 -C 7 alkyl
- R5 is -C(O)OR8 and R8 is hydrogen, C 1 -C 7 alkyl or C 3 -C 7 cycloalkyl.
- Xanthine oxidase is known as an enzyme that converts hypoxanthine to xanthine and also formed xanthine to uric acid. Since uricase, which is present in most mammals, is absent in humans and chimpanzees, uric acid is known to be the last product of purine metabolism (S. P. Bruce, Ann. Pharm., 2006, 40, 2187). ⁇ 2194). Uric acid maintained at a high concentration in the blood causes various diseases, including gout as a representative example.
- gout is a disease caused by a high level of uric acid in the body, and refers to a condition in which uric acid crystals are accumulated in cartilage, ligaments, and surrounding tissues of the joint, causing severe inflammation and pain. Gout is a type of inflammatory joint disease, and its incidence has been steadily increasing over the past 40 years (N. L. Edwards, Arthritis & Rheumatism, 2008, 58, 2587-2590).
- the number of gout patients in the West increased by 200-300%, and it is mainly found in men. Obesity, aging, decreased renal function, and hypertension are considered to be the causes of this increase in gout patients. If you look at the incidence of gout, the level is about 1.4/1000, but this also shows different results depending on the level of uric acid. In other words, the incidence of gout was 0.5% in the group of patients with blood uric acid levels of 7.0 mg/dl or higher, whereas the incidence of gout was 5.5% in the group of patients with uric acid levels above 9.0 mg/dl (G. Nuki, Medicine, 2006, 34, 417-423).
- Allopurinol is known as a non-specific inhibitor of various enzymes involved in purine and pyrimidine metabolism, and has a Ki 700 nM for xanthine oxidase (Y. Takano et al., Life Sciences, 2005, 76, 1835-1847). . It is known that allopurinol is oxidized by xanthine oxidase and converted to oxypurinol, and this metabolite acts as a very strong inhibitor of xanthine oxidase.
- Korean Patent Publication No. 10-2011-0037883 discloses a novel compound of Formula 1 effective as a xanthine oxidase inhibitor:
- A is selected from the following substituents A-i, A-ii, A-iii, A-iv, A-v, A-vi, A-vii and A-viii;
- J represents hydrogen, halogen, or C 1 -C 6 -alkyl substituted or unsubstituted by halogen
- X is O or S
- Z is C or N
- E represents hydrogen, halogen, cyano, nitro, substituted or unsubstituted C 1 -C 6 -alkyl, or substituted or unsubstituted C 1 -C 6 -alkoxy,
- Q is selected from the following substituents Q-i, Q-ii, Q-iii-1 to Q-iii-9,
- W represents O or S
- R7 represents hydrogen or substituted or unsubstituted lower alkyl
- n is an integer from 0 to 3
- R8 and R9 each independently represent hydrogen or lower alkyl, and m is an integer of 1 to 3);
- R10 and R11 each independently represent hydrogen, halogen, lower alkoxy or lower alkyl, and m is an integer of 1 to 3;
- R12 represents substituted or unsubstituted lower alkyl or aromatic, and n is an integer from 0 to 3;
- R13 and R14 each independently represent a substituted or unsubstituted lower alkyl, or may form a 3-7 membered heterocycle including N, and n is an integer of 0-3);
- R15 represents substituted or unsubstituted lower alkyl, and m is an integer of 1 to 3;
- R15 represents substituted or unsubstituted lower alkyl, and m is an integer of 1 to 3;
- Y represents hydrogen, halogen, substituted or unsubstituted linear, branched or cyclic saturated or unsaturated alkyl, substituted or unsubstituted C 1 -C 6 -alkoxy, substituted or unsubstituted aromatic, or heteroaromatic,
- G represents hydrogen or substituted or unsubstituted linear, branched or cyclic saturated or unsaturated alkyl.
- an object of the present invention is to provide a method suitable for mass production of the compound of Formula 2, which is a key intermediate in the synthesis of an excellent xanthine oxidase inhibitor, at a lower cost.
- a method for preparing a compound of Formula 2 by reacting a compound of Formula 3 with a compound of Formula 4 with a copper catalyst, a base and a ligand in an organic solvent for C-N coupling reaction:
- X is F, Cl, Br or I
- R1 is hydrogen
- R2 is hydrogen, halogen, C 1 -C 7 alkyl, C 1 -C 7 alkoxy-C 1 -C 7 alkyl or phenyl;
- R3 is hydrogen; C 1 -C 7 alkyl unsubstituted or substituted by a substituent selected from halogen, C 3 -C 7 cycloalkyl and O-R 6 , wherein R 6 represents C 1 -C 4 alkyl; C 3 -C 7 cycloalkyl; or (wherein W represents O or S, R7 represents hydrogen or C 1 -C 4 alkyl, and n is an integer from 0 to 3);
- R4 is hydrogen, halogen or C 1 -C 7 alkyl
- R5 is -C(O)OR8 and R8 is hydrogen, C 1 -C 7 alkyl or C 3 -C 7 cycloalkyl.
- the intermediate compound of Formula 2 is synthesized by a C-N coupling reaction between the compound of Formula 3 and the compound of Formula 4.
- the organic solvent in the method may be, for example, one or more selected from xylene, toluene, dimethylformamide (DMF), and dimethylsulfoxide (DMSO).
- the copper catalyst in the method may be, for example, one or more selected from CuI, Cu(OAc) 2 , Cu, Cu 2 O and CuO.
- the base in the process is, for example, potassium carbonate (K 2 CO 3 ), cesium carbonate (Cs 2 CO 3 ), potassium triphosphate (K 3 PO 4 ), triethylamine (Et) 3 N) and at least one selected from sodium tert-butoxide (NaOtBu) may be used.
- the ligand in the method is, for example, 1,2-cyclohexanediamine, N,N' -dimethyl-1,2-cyclohexanediamine ( N,N ' -dimethyl-1,2-cyclohexanediamine), N,N' -dimethylethylenediamine ( N,N' -dimethylethylenediamine), 1,10-phenanthroline (1,10-phenanthroline), proline, oxime ( At least one selected from oxime) ligands and tetradentate ligands may be used.
- the preparation method of the present invention can mass-produce the intermediate of Chemical Formula 2 in high yield by introducing the compound of Chemical Formula 3, which is commercially available for mass purchase, and simplifying the process to enable scale-up.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (5)
- 화학식 3의 화합물과 화학식 4의 화합물을 유기용매 하에서 구리촉매, 염기 및 리간드와 함께 C-N 커플링 반응하는 것을 포함하는 화학식 2의 화합물의 제조 방법:[화학식 2][화학식 3][화학식 4]상기 화학식에서,X는 F, Cl, Br 또는 I이고,R1은 수소이며;R2는 수소, 할로겐, C1-C7 알킬, C1-C7 알콕시-C1-C7 알킬 또는 페닐이고;R3는 수소; 비치환 또는 할로겐, C3-C7 사이클로알킬 및 O-R6에서 선택된 치환체에 의해서 치환된 C1-C7 알킬(여기에서 R6는 C1-C4 알킬을 나타낸다); C3-C7 사이클로알킬; 또는 (여기에서 W는 O 또는 S를 나타내고, R7은 수소 또는 C1-C4 알킬을 나타내며, n은 0 내지 3의 정수이다)이며;R4는 수소, 할로겐 또는 C1-C7 알킬이고;R5는 -C(O)OR8이고, R8은 수소, C1-C7 알킬 또는 C3-C7 사이클로알킬이다.
- 제1항에 있어서, 상기 유기용매가 자일렌, 톨루엔, 디메틸포름아마이드(DMF), 디메틸설폭사이드(DMSO)로부터 선택되는 하나 이상인 것을 특징으로 하는 제조 방법.
- 제1항에 있어서, 상기 구리촉매가 CuI, Cu(OAc)2, Cu, Cu2O 및 CuO로부터 선택되는 하나 이상인 것을 특징으로 하는 제조 방법.
- 제1항에 있어서, 상기 염기가 탄산칼륨, 탄산세슘, 제삼인산칼륨, 트리에틸아민 및 소듐 tert-부톡사이드로부터 선택되는 하나 이상인 것을 특징으로 하는 제조 방법.
- 제1항에 있어서, 상기 리간드가 1,2-사이클로헥산디아민, N,N'-디메틸-1,2-사이클로헥산디아민, N,N'-디메틸에틸렌디아민, 1,10-페난트롤린, 프롤린, 옥심 리간드 및 테트라덴테이트 리간드로부터 선택되는 하나 이상인 것을 특징으로 하는 제조 방법.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/557,775 US20240262809A1 (en) | 2021-04-27 | 2022-04-26 | Method for preparing intermediate for synthesis of xanthine oxidase inhibitor |
CN202280031162.4A CN117242062A (zh) | 2021-04-27 | 2022-04-26 | 用于合成黄嘌呤氧化酶抑制剂的中间体的制备方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2021-0054150 | 2021-04-27 | ||
KR20210054150 | 2021-04-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022231261A1 true WO2022231261A1 (ko) | 2022-11-03 |
Family
ID=83848346
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/005925 WO2022231261A1 (ko) | 2021-04-27 | 2022-04-26 | 잔틴 옥시다아제 저해제 합성을 위한 중간체의 제조 방법 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20240262809A1 (ko) |
CN (1) | CN117242062A (ko) |
WO (1) | WO2022231261A1 (ko) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007043457A1 (ja) * | 2005-10-07 | 2007-04-19 | Astellas Pharma Inc. | トリアリールカルボン酸誘導体 |
WO2008126898A1 (ja) * | 2007-04-11 | 2008-10-23 | Kissei Pharmaceutical Co., Ltd. | (アザ)インドール誘導体及びその医薬用途 |
KR20110037883A (ko) * | 2009-10-07 | 2011-04-13 | 주식회사 엘지생명과학 | 잔틴 옥시다아제 저해제로서 효과적인 신규 화합물, 그 제조방법 및 그를 함유하는 약제학적 조성물 |
-
2022
- 2022-04-26 WO PCT/KR2022/005925 patent/WO2022231261A1/ko active Application Filing
- 2022-04-26 CN CN202280031162.4A patent/CN117242062A/zh active Pending
- 2022-04-26 US US18/557,775 patent/US20240262809A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007043457A1 (ja) * | 2005-10-07 | 2007-04-19 | Astellas Pharma Inc. | トリアリールカルボン酸誘導体 |
WO2008126898A1 (ja) * | 2007-04-11 | 2008-10-23 | Kissei Pharmaceutical Co., Ltd. | (アザ)インドール誘導体及びその医薬用途 |
KR20110037883A (ko) * | 2009-10-07 | 2011-04-13 | 주식회사 엘지생명과학 | 잔틴 옥시다아제 저해제로서 효과적인 신규 화합물, 그 제조방법 및 그를 함유하는 약제학적 조성물 |
Non-Patent Citations (2)
Title |
---|
HA PHA, NGUYEN OANH, HUYNH KHOA, NGUYEN TUNG, PHAN NAM: "Synthesis of Unnatural Arundines Using a Magnetically Reusable Copper Ferrite Catalyst", SYNLETT, GEORG THIEME VERLAG, DE, vol. 29, no. 15, 1 September 2018 (2018-09-01), DE , pages 2031 - 2034, XP055980295, ISSN: 0936-5214, DOI: 10.1055/s-0037-1610227 * |
YEH, V.S.C. ; WIEDEMAN, P.E.: "Practical Cu-catalyzed amination of functionalized heteroaryl halides", TETRAHEDRON LETTERS, ELSEVIER, AMSTERDAM , NL, vol. 47, no. 34, 21 August 2006 (2006-08-21), Amsterdam , NL , pages 6011 - 6016, XP025004687, ISSN: 0040-4039, DOI: 10.1016/j.tetlet.2006.06.119 * |
Also Published As
Publication number | Publication date |
---|---|
US20240262809A1 (en) | 2024-08-08 |
KR20220147529A (ko) | 2022-11-03 |
CN117242062A (zh) | 2023-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101751325B1 (ko) | 잔틴 옥시다아제 저해제로서 효과적인 신규 화합물, 그 제조방법 및 그를 함유하는 약제학적 조성물 | |
KR960001722B1 (ko) | 카르보스티릴유도체 및 그것을 함유한 의약조성물 | |
US6965036B2 (en) | Intermediates for guanidine mimics as factor Xa inhibitors | |
US4935420A (en) | Benzoheterocyclic compounds | |
EA015516B1 (ru) | Ингибиторы 11-бета-гидроксистероид дегидрогеназы 1 | |
AU2018308038B2 (en) | Improved process for preparing aminopyrimidine derivatives | |
CN101018788A (zh) | 吡咯并[3,2-c]吡啶衍生物及其制备方法 | |
CA2531912A1 (en) | Process for producing 1,2,4-triazole compound and intermediate therefor | |
WO2022231261A1 (ko) | 잔틴 옥시다아제 저해제 합성을 위한 중간체의 제조 방법 | |
EA016814B1 (ru) | Замещенные изотопами ингибиторы протонного насоса | |
AU2018308039B2 (en) | Novel intermediates useful for the synthesis of aminopyrimidine derivatives, process for preparing the same, and process for preparing aminopyrimidine derivatives using the same | |
WO2022231263A1 (ko) | 잔틴 옥시다아제 저해제 합성을 위한 중간체의 제조 방법 | |
CN114835640B (zh) | 成纤维细胞生长因子受体抑制剂、制备方法及应用 | |
WO2022231262A1 (ko) | 잔틴 옥시다아제 저해제의 제조 방법 | |
JP2007522181A (ja) | シクロオキシゲナーゼ−1及びシクロオキシゲナーゼ−2阻害剤としての置換アゼチジン化合物、ならびにそれらの調製、および薬剤としての使用 | |
KR102708080B1 (ko) | 잔틴 옥시다아제 저해제 합성을 위한 중간체의 제조 방법 | |
JP2005041802A (ja) | 1,2,4−トリアゾール化合物の製造方法 | |
KR102708081B1 (ko) | 잔틴 옥시다아제 저해제 합성을 위한 중간체의 제조 방법 | |
US20060189811A1 (en) | Process for producing 1,2,4-triazole compound and intermediate therefor | |
EP0230622A1 (en) | 6H-Isoxazol[5,4-d]pyrazolo[3,4-b]pyridines, a process and intermediates for their preparation and their use as medicaments | |
AU2004254226B2 (en) | 2,4-bis(trifluoroethoxy)pyridine compound and medicine containing the same | |
KR100824233B1 (ko) | 사이클로옥시게나제-2의 저해제로서 선택성이 뛰어난3,4-디하이드로-1h-나프탈렌 유도체 | |
TR2023013440T2 (tr) | Ksanti̇n oksi̇daz i̇nhi̇bi̇törü hazirlamaya yöneli̇k yöntem | |
WO2011120312A1 (zh) | 3-氰基-1-(2,6-二氯-4-三氟甲基苯基)吡唑衍生物杀虫剂 | |
WO2023200189A1 (ko) | 3-페닐-2,3,4,8,9,10-헥사히드로피라노[2,3-f]크로멘 유도체의 합성 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22796094 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023/013421 Country of ref document: TR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 112023000172089 Country of ref document: IT |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280031162.4 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18557775 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22796094 Country of ref document: EP Kind code of ref document: A1 |